Want to see HK:0474 full AI Analyst Report?
0474 Stock Chart & Stats
HK$0.12
>-HK$0.01(-2.00%)
At close: 4:00 PM EST
HK$0.12
>-HK$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeHK$0.04 - HK$0.16
Previous CloseN/A
Volume12.00K
Average Volume (3M)5.34M
Market Cap
HK$1.26B
Enterprise ValueHK$1.89K
Total Cash (Recent Filing)HK$345.00M
Total Debt (Recent Filing)HK$1.19B
Price to Earnings (P/E)3.0
Beta0.11
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.2%
Share Statistics
EPS (TTM)0.05
Shares Outstanding8,858,127,000
10 Day Avg. Volume2,008,821
30 Day Avg. Volume5,339,116
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.53
Price to Sales (P/S)10.91
P/FCF Ratio34.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability ReboundThe return to reported profitability improves near-term financial resilience and may support reinvestment or debt servicing. However, the rebound should be monitored because weak operating margins indicate that its durability is not yet established.
Positive Free Cash FlowPositive recent free cash flow indicates the business is again generating cash after the 2024 shortfall. This provides some internal funding capacity, although the modest scale and prior volatility limit confidence in sustained cash generation.
Balance-sheet RepairLower debt and higher equity provide a stronger capital base than in 2025, potentially reducing immediate refinancing pressure and improving financial flexibility. The benefit is meaningful but incomplete because leverage remains heavy.
Bears Say
Sharp Revenue ContractionA steep decline in revenue highlights an unstable top-line trajectory and makes fixed-cost absorption more difficult. Unless demand and business activity recover, the contraction can constrain operating leverage and undermine the recent earnings rebound.
Weak Operating ProfitabilityPersistently weak operating margins suggest the core business has not yet demonstrated durable profitability. The gap between operating performance and net income raises the risk that reported earnings depend on non-operating or one-off items.
Heavy Leverage And Uneven Cash ConversionHigh leverage increases financial risk and leaves less room to absorb weak trading conditions. Declining recent free cash flow and historically inconsistent cash conversion further limit the company’s ability to reduce debt through internally generated funds.
Aceso Life Science Group Limited News
0474 FAQ
What was Aceso Life Science Group Limited’s price range in the past 12 months?
Aceso Life Science Group Limited lowest stock price was HK$0.04 and its highest was HK$0.16 in the past 12 months.
What is Aceso Life Science Group Limited’s market cap?
Aceso Life Science Group Limited’s market cap is HK$1.26B.
When is Aceso Life Science Group Limited’s upcoming earnings report date?
Aceso Life Science Group Limited’s upcoming earnings report date is Dec 01, 2026 which is in 65 days.
How were Aceso Life Science Group Limited’s earnings last quarter?
Aceso Life Science Group Limited released its earnings results on Jun 26, 2026. The company reported -HK$0.005 earnings per share for the quarter.
Is Aceso Life Science Group Limited overvalued?
According to Wall Street analysts Aceso Life Science Group Limited’s price is currently Overvalued.
Does Aceso Life Science Group Limited pay dividends?
Aceso Life Science Group Limited pays a Annually dividend of HK$0.06 which represents an annual dividend yield of 1.2%. See more information on Aceso Life Science Group Limited dividends here
What is Aceso Life Science Group Limited’s EPS estimate?
Aceso Life Science Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aceso Life Science Group Limited have?
Aceso Life Science Group Limited has 8,858,127,000 shares outstanding.
What happened to Aceso Life Science Group Limited’s price movement after its last earnings report?
Aceso Life Science Group Limited reported an EPS of -HK$0.005 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aceso Life Science Group Limited?
Currently, no hedge funds are holding shares in HK:0474
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aceso Life Science Group Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
215.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aceso Life Science Group Limited
Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom. It operates through rental and sale of construction machinery and spare parts business; provision of repair and maintenance and transportation service business; money lending business; provision of asset management, securities brokerage and other financial service business; property leasing business; and property development business segments. The company leases and sells construction machinery, including crawler cranes, mobile cranes, aerial platforms, and foundation equipment, as well as spare parts; and sells construction materials. It also provides repair and maintenance services for construction machinery; transportation services, such as local container delivery, construction site delivery, and heavy machinery transport; mortgaged and personal loans; and money lending, asset management, commodities, futures, securities brokerage, and other financial services. In addition, the company retails men's and women's apparel; and provides group management, administration, and securities investment services. Further, the company involved in trading of futures and bioscience; and urban development businesses. The company was formerly known as Hao Tian Development Group Limited and changed its name to Aceso Life Science Group Limited in October 2020. Aceso Life Science Group Limited was founded in 1985 and is based in Wan Chai, Hong Kong.